GlassScriptPhysician profile
Inna Milgram
NPI 1932197597
$7,947.31
in general payments reported to CMS, 2019-2025
30 companies · $860 in 2025
The $860 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,389 · 2020: $1,403 · 2021: $1,365 · 2022: $948 · 2023: $1,124 · 2024: $859 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,843.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,698.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,215.91 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $1,022.43 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $996.31 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $469.65 | 2019-2023 | Arexvy, Shingrix |
| Pfizer INC. | $461.04 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $335.97 | 2019-2024 | Xarelto |
| Abbvie INC. | $289.51 | 2021-2025 | |
| Exact Sciences Corporation | $242.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $170.53 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $136.87 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.46 | 2019-2021 | |
| Adlon Therapeutics L.P. | $99.29 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $87.98 | 2020-2022 | |
| Sanofi Pasteur INC. | $76.51 | 2019-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $70.08 | 2019-2020 | |
| Amgen INC. | $68.39 | 2020-2022 | |
| Genentech USA, INC. | $54.66 | 2019-2021 | |
| Astellas Pharma US INC | $48.67 | 2020-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $43.10 | 2019 | |
| Nestle Healthcare Nutrition INC. | $37.24 | 2023 | |
| Sanofi-Aventis U.S. LLC | $36.65 | 2019 | |
| Azurity Pharmaceuticals, INC. | $35.77 | 2024-2025 | |
| Cranial Technologies, INC | $34.58 | 2022-2023 | Doc Band |
| Horizon Therapeutics Plc | $25.16 | 2020 | |
| Corcept Therapeutics | $18.92 | 2024 | Korlym |
| Shire North American Group INC | $16.97 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.50 | 2021 | |
| Circassia INC. | $13.02 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Milgram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.